×
About 599 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  281 results

Clinical Characteristics and Burden of Disease in Prurigo Nodularis.
https://doi.org/10.1111/ced.14722
Clinical and Experimental Dermatology; Aggarwal P, Choi J et. al.

May 10th, 2021 - Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense pruritus, but information on patient experience and impact on quality of life (QoL) remains understudied. To characterize disease characteristics and QoL in a g...

A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in t...
https://doi.org/10.1016/j.jid.2021.02.756
The Journal of Investigative Dermatology; Wongvibulsin S, Sutaria N et. al.

Apr 6th, 2021 - A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.|2021|Wongvibulsin S,Sutaria N,Williams KA,Huang AH,Choi J,|

Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polariz...
https://doi.org/10.1016/j.jid.2021.02.749
The Journal of Investigative Dermatology; Belzberg M, Alphonse MP et. al.

Mar 27th, 2021 - Prurigo nodularis (PN) is an understudied, chronic inflammatory skin disease that disproportionately affects African Americans and presents with intensely pruritic nodules of unknown etiology. To better characterize the immune dysregulation in PN,...

Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A R...
https://doi.org/10.1016/j.jaad.2021.02.038
Journal of the American Academy of Dermatology; Georgakopoulos JR, Croitoru D et. al.

Feb 22nd, 2021 - Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A Retrospective Cohort Study.|2021|Georgakopoulos JR,Croitoru D,Felfeli T,Alhusayen R,Lansang P,|

Real-world disease burden and comorbidities of pediatric prurigo nodularis.
https://doi.org/10.1016/j.jaad.2021.02.030
Journal of the American Academy of Dermatology; Huang AH, Roh YS et. al.

Feb 18th, 2021 - Real-world disease burden and comorbidities of pediatric prurigo nodularis.|2021|Huang AH,Roh YS,Sutaria N,Choi J,Williams KA,|

see more →

Clinicaltrials.gov  293 results

Clinical Characteristics and Burden of Disease in Prurigo Nodularis.
https://doi.org/10.1111/ced.14722
Clinical and Experimental Dermatology; Aggarwal P, Choi J et. al.

May 10th, 2021 - Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense pruritus, but information on patient experience and impact on quality of life (QoL) remains understudied. To characterize disease characteristics and QoL in a g...

Study Enhances Understanding of 'Tremendously Understudied' Prurigo Nodularis
https://www.medscape.com/viewarticle/949495

Apr 18th, 2021 - Patients with prurigo nodularis tend to make a greater number of visits to health care specialists and are burdened by a greater number of medical comorbidities, compared with age-matched controls, as well those with atopic dermatitis and psoriasi...

A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in t...
https://doi.org/10.1016/j.jid.2021.02.756
The Journal of Investigative Dermatology; Wongvibulsin S, Sutaria N et. al.

Apr 6th, 2021 - A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.|2021|Wongvibulsin S,Sutaria N,Williams KA,Huang AH,Choi J,|

Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polariz...
https://doi.org/10.1016/j.jid.2021.02.749
The Journal of Investigative Dermatology; Belzberg M, Alphonse MP et. al.

Mar 27th, 2021 - Prurigo nodularis (PN) is an understudied, chronic inflammatory skin disease that disproportionately affects African Americans and presents with intensely pruritic nodules of unknown etiology. To better characterize the immune dysregulation in PN,...

Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A R...
https://doi.org/10.1016/j.jaad.2021.02.038
Journal of the American Academy of Dermatology; Georgakopoulos JR, Croitoru D et. al.

Feb 22nd, 2021 - Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A Retrospective Cohort Study.|2021|Georgakopoulos JR,Croitoru D,Felfeli T,Alhusayen R,Lansang P,|

see more →

News  25 results

Study Enhances Understanding of 'Tremendously Understudied' Prurigo Nodularis
https://www.medscape.com/viewarticle/949495

Apr 18th, 2021 - Patients with prurigo nodularis tend to make a greater number of visits to health care specialists and are burdened by a greater number of medical comorbidities, compared with age-matched controls, as well those with atopic dermatitis and psoriasi...

Nemolizumab tames itching in prurigo nodularis patients in phase 2 study
https://www.mdedge.com/dermatology/article/217918/medical-dermatology/nemolizumab-tames-itching-prurigo-nodularis-patients?channel=39212
Heidi Splete

Feb 26th, 2020 - Adults with moderate to severe prurigo nodularis who were treated with the investigational drug nemolizumab showed significant improvement in itching, compared with patients treated with placebo, according to data from a phase 2 trial of 70 patien.

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.staging.medscape.com/viewarticle/925465

Feb 20th, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.medscape.com/viewarticle/925465

Feb 20th, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Rapid improvement seen with nemolizumab for prurigo nodularis in phase 2b study
https://www.mdedge.com/dermatology/article/211733/medical-dermatology/rapid-improvement-seen-nemolizumab-prurigo-nodularis?channel=39313
Bruce Jancin

Nov 6th, 2019 - MADRID – Nemolizumab, an investigational humanized monoclonal antibody targeting the interleukin-31 receptor alpha subunit, achieved rapid and clinically meaningful improvement in both itch and skin lesions of severe prurigo nodularis in a phase 2.

see more →